Table of Contents

Key Takeaways

  • Long-term spike detection does not require genomic integration or an immortal producer cell. A finite template, durable membrane-bound protein, and vesicle transport can account for it. [HYPOTHESIS]
  • The relay layer is measured, not inferred: ~70% of internalized LNP cargo is exocytosed back out via the vesicle machinery with only 1-2% reaching the cytosol (Sahay 2013); LNP mRNA and ionizable lipid leave cells inside EVs and the mRNA still translates in recipient cells (Maugeri 2019); spike-bearing exosomes circulate by day 14 after a first dose (Bansal 2021).
  • Calibration: the published patisiran ionizable-lipid terminal half-life is 14.6-28.7 days (Zhang 2020), not the ~60 days the frame is often quoted with; and the 70% re-export figure is in vitro siRNA-LNP work, not a clinical Onpattro measurement.
  • Not yet measured anywhere: ionizable lipid inside vaccine-derived EVs in humans. The infection-EV versus LNP-EV cargo difference is proposed, not established.

Why this article exists#

There is a standing objection to everything this site documents about persistent spike. It runs: modified mRNA degrades within days, free protein clears within weeks, so spike detected months after injection implies either genomic integration or a chronic producer, meaning infection or something like it. Both implications are serious. Neither is required.

A third explanation exists, each of whose layers is already in the published literature: the transfected cell is finite, the protein it made is durable, and the cell's own vesicle machinery can carry lipid, RNA fragments and protein out to other sites. The frame for putting those three layers together is not mine. It belongs to a pharmacist, Maria Gutschi, writing as @CanningPharm. This article holds her frame against the primary literature, corrects two numbers that usually travel with it, and wires it into this site's persistence cluster.

Tagged HYPOTHESIS. The layers underneath are graded separately, and the grading matters: what is measured, what is analogous, and what is proposed are kept apart throughout.

Credit where it belongs#

The Index / Persistence / Relay frame is Gutschi's, published in her thread (X, @CanningPharm) and expanded in her Substack essay (The Exosome Problem). Nothing in this article modifies or extends her model. What this article adds is the site's standard treatment: primary sourcing for every load-bearing claim, calibration of the two figures that get quoted loosely, explicit refutation criteria, and crosslinks into the persistence articles this site already carries.

Layer 1: the index cell, a finite template#

The first transfected cell receives a finite amount of modified mRNA. Early public statements put its life at a few days. The measured picture is longer, and still bounded.

In axillary lymph-node biopsies after mRNA vaccination, Röltgen and colleagues detected vaccine mRNA, and spike protein, in germinal centres out to 60 days PP · HIGH for the detection finding itself, a small biopsy series. Sixty days is roughly an order of magnitude beyond the few-days figure, and it is not forever.

The plasma kinetics agree. Ogata and colleagues, using ultrasensitive Single Molecule Array assays in 13 recipients of mRNA-1273, found circulating S1 in 11 of 13 participants from day 1 after the first dose, peaking around day 5, no longer detectable by day 14, and absent after the second dose PP · MODERATE, n=13. Antigen appearance in plasma is early, and its clearance tracks the rise of the antibody response.

Layer 1 is a real but bounded template. MECHANISTIC · MODERATE as a general statement, carried by the two human series above.

Layer 2: persistence, protein after the template#

The same two papers carry the second layer. In Ogata's series, plasma S1 is present while the template is being consumed: protein, once made, exists on a timescale of its own. In Röltgen's biopsies, spike protein sits in germinal centres alongside detectable mRNA at 60 days, that is, deposited antigen in tissue, not circulating antigen in plasma.

The site's persistence cluster documents the downstream of this: durable antigen display, reservoirs, and the failure of clearance that lets it matter clinically. This layer is where the relay article meets that cluster, and the crosslinks at the end of this article are that connection made explicit.

Layer 3: the relay, out through the vesicle machinery#

This is the layer the objection never accounts for, and it is the best-measured of the three.

The quantitative baseline comes from siRNA-LNP work: of internally delivered LNP cargo, roughly 1-2% reaches the cytosol, while around 70% is exocytosed back out of the cell through recycling endosomes and multivesicular bodies AN · HIGH for the in vitro quantification. The dominant fate of endocytosed LNP contents is exit, and the exit route is the same machinery that manufactures exosomes.

Maugeri and colleagues then showed the exit is functional, for an LNP-mRNA product in vitro: mRNA and ionizable lipid that had escaped endosomes were loaded into extracellular vesicles and released, and vesicle-delivered mRNA was translated in recipient cells AN · HIGH. Ionizable lipid travels in the vesicles. That single point does a lot of work, and it is measured, in that system.

And in vaccinated humans, Bansal and colleagues found circulating exosomes carrying spike protein by day 14 after the first BNT162b2 dose, with anti-spike antibodies appearing on the same timescale after the second PP · MODERATE. The relay is not only a culture phenomenon. Vesicle-borne spike is observable in people.

The three layers as one diagram, redrawn from the frame above rather than linked from it:

flowchart LR A["Index cell: finite modified mRNA"] --> B["Translation: spike protein"] A --> C["Endosome / multivesicular body"] C -->|"1-2% escapes to cytosol"| D["Cytosolic mRNA, translated"] C -->|"~70% recycled outward"| E["Exosomes: lipid, RNA fragments, spike"] B --> F["Spike on membranes and in tissue, durable"] B --> G["Plasma S1: days 1-14, then cleared"] E --> H["Recipient cells at distant sites"] H --> I["Translated or displayed spike, antigen presented"]

An LNP dose adds one thing natural infection does not: a bulk deposit of membrane-active ionizable lipid into the endosomal system of the transfected cell, the same compartment that ships vesicles. Maugeri's ionizable-lipid-in-EV finding is the reason this difference is more than hand-waving. Whether vaccine-derived EVs in humans carry ALC-0315 or SM-102 inside them has not been measured; that distinction between infection-generated and LNP-generated vesicles is proposed, and the confirmation section below names the measurement that would settle it.

The closest licensed analog, calibrated#

Gutschi's essay leans on Onpattro (patisiran), the one licensed LNP RNA drug with full public pharmacokinetics, as the analog for what cells do with internalized LNP. The published clinical PK supports a biphasic-plus picture: rapid distribution clearance, then a minor secondary peak, then a long terminal phase, with the ionizable lipid DLin-MC3-DMA showing a terminal half-life of 14.6 to 28.7 days, against 3.2 ± 1.8 days for the siRNA itself PP · HIGH for the PK as published. A secondary peak is what redistributed lipid coming back out of tissue looks like, which is at least consistent with cells taking LNP up and sending components back out.

Two calibrations, because the numbers that circulate with this frame are looser than their sources:

  1. The ~60-day lipid half-life quoted in the essay is not what the primary source says. The published terminal half-life of DLin-MC3-DMA in humans is 14.6 to 28.7 days. This article carries the published range.
  2. The 70% re-export figure is Sahay's in vitro siRNA-LNP quantification, not a clinical Onpattro measurement. It is the right order for the argument, and it is in vitro.

The analogy itself is graded [HYPOTHESIS], LOW-MODERATE: patisiran is an intravenous siRNA product cleared into hepatocytes, the vaccines are intramuscular mRNA products draining to node and tissue. Different cargo, different route, different organ. The analog tells you what cells can do with internalized LNP. It does not tell you what these products did.

What the model explains#

  • Detection without integration. The site's insertional-mutagenesis defence piece is careful about integration claims. This frame is the mechanism that does the work integration is usually invoked for: persistence of antigen without any change to the genome. insertional-mutagenesis defence
  • Distribution. Antigen and lipid found far from the injection site and its draining nodes do not require cells to migrate. Vesicles go with the circulation.
  • Re-seeding during the tolerance window. The tolerance-gate article asks what would confirm a window in which antigen is detected loudly and cleared quietly. Antigen arriving in vesicles while the gate is open is exactly that observation class. why spike persists: the tolerance gate
  • Persistent antigenic drive. The persistence cluster documents that spike stays detectable and that clearance fails. The relay supplies a way for presentation to continue after the producer cell is gone. spike persistence, microclots, reactivated viruses

What this article is not claiming#

  • No integration claim. The frame works precisely because integration is not needed.
  • No immortal factory. The index cell is finite; on this model the vesicle output is bounded by what the index cell and its neighbours took up, minus clearance.
  • No dosimetry. Nothing here converts vesicle counts into any quantity per dose.
  • The infection-EV versus LNP-EV cargo difference is proposed, not established. One half of it, ionizable lipid travelling in EVs, is measured in vitro (Maugeri). The other half, vaccine-derived EVs carrying ALC-0315 or SM-102 in humans, is measured nowhere yet.
  • Small-n primaries are stated as such. Ogata is 13 participants, Bansal a small longitudinal cohort, Röltgen a biopsy series. Peer-reviewed human data with small n is still small n, and the register below says so at every line.

What would confirm it#

  • Isolation of EV fractions from vaccinated plasma containing the vaccine ionizable lipids, ALC-0315 or SM-102, by mass spectrometry.
  • EV RNA sequencing showing vaccine-sequence RNA in vesicle fractions weeks after dosing.
  • A time course in which vesicle-borne antigen persists on the protein's timescale rather than the template's.

What would refute it#

  • Competent EV isolation across cohorts finding neither vaccine-sequence RNA nor spike in vesicle fractions.
  • Kinetics in which vesicle-borne antigen tracks the template and disappears with it, which would make the relay a shadow of layer 1 rather than a mechanism of its own.

Citation register (calibrated)#

  • Ogata AF, Cheng C-A, Desjardins M, et al. Circulating SARS-CoV-2 vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis. 2022;74(4):715-718. PMID 34015087. DOI 10.1093/cid/ciab465. PMC8241425. [PP, n=13]
  • Röltgen K, et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell. 2022;185(6):1025-1040. PMID 35148837. DOI 10.1016/j.cell.2022.01.018. [PP, biopsy series]
  • Maugeri M, et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat Commun. 2019;10:4333. PMID 31551417. DOI 10.1038/s41467-019-12275-6. [AN, in vitro]
  • Sahay G, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013;31:653-658. PMID 23792629. DOI 10.1038/nbt.2614. PMC3814166. [AN, in vitro quantification]
  • Bansal S, et al. Cutting Edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 mRNA vaccination. J Immunol. 2021;207(10):2405-2410. PMID 34654691. DOI 10.4049/jimmunol.2100637. [PP, small cohort]
  • Zhang X, et al. Pharmacokinetics of patisiran, the first approved RNA interference therapy, in patients with hereditary transthyretin-mediated amyloidosis. J Clin Pharmacol. 2020. PMID 31777097. DOI 10.1002/jcph.1553. PMC7187331. [PP, clinical PK]
  • Gutschi M. The exosome frame: Index, Persistence, Relay. Thread, X/@CanningPharm, 2026: link. Essay: link. [secondary frame, not a primary source]

Open to corrections#

Every number here is traceable to the register above, and the two corrections to the circulating figures are stated in the analog section, not buried. If something here is wrong, tell me and it gets corrected with the same prominence as the original claim. General policy on the Methodology page.

End of exosome relay article. The HYPOTHESIS tag comes off the relay layer the day someone publishes ALC-0315 or SM-102 inside EV fractions from vaccinated plasma. The refutation criteria above are the other way out.